Obe-cel provides consistent efficacy and safety for relapsed or refractory B-ALL regardless of EMD status
ae H Park, MD, of Memorial Sloan Kettering Cancer Center in New York, and colleagues presented the findings at the Fourteenth Annual Meeting
Acute Lymphoblastic Leukemia News
SOHO 2026
Multiple Myeloma News
SOHO 2026
Meetings / Conferences
Oral cryotherapy, amifostine, uproleselan improve mucositis, GI toxicity related to high-dose melphalan conditioning prior to ASCT
Amifostine and uproleselan also showed “meaningful promise” for reducing mucositis and delaying severe diarrhea and improving GI quality of life, respectively, but require
Multiple Myeloma News
SOHO 2026
Meetings / Conferences
Anselamimab offers significant reduction in all-cause mortality and cardiovascular hospitalization risk for kappa AL amyloidosis
The study, led by Ashutosh Wechalekar, MD, of National Amyloidosis Centre and University College London Hospitals in the United Kingdom, analyzed a combined
Multiple Myeloma News
SOHO 2026
Meetings / Conferences
Arlo-cel, an anti-GPRC5D CAR T-cell, achieves deep and durable responses for patients with relapsed or refractory multiple myeloma in phase 1 trial
Final results from the first-in-human phase 1 study of arlo-cel represent the longest follow-up with GPRC5D CAR T-cell therapy in relapsed or refractory
SOHO 2026
Meetings / Conferences
News
MDS Roundtable
Analysis shows marked difference in treatment patterns, survival between MDS risk groups
The study, led by Raúl Azibeiro Melchor, of Hospital Universitario de Salamanca in Spain, will be presented at the Fourteenth Annual Meeting of
MDS News
SOHO 2026
Meetings / Conferences
Telomere disorders linked to substantial morbidity, clonal hematopoiesis
Patients with telomere biology disorders (TBDs) exhibited substantial hematologic and multiorgan morbidity as well as frequent clonal hematopoiesis with a high rate of
Acute Lymphoblastic Leukemia News
SOHO 2026
Meetings / Conferences
News
Extended analysis shows long-term benefit with obe-cel in relapsed or refractory B-ALL
The analysis, led by Elias Jabbour, MD, of University of Texas MD Anderson Cancer Center in Houston, was presented at the Fourteenth Annual
MDS News
SOHO 2026
Meetings / Conferences
Myelodysplastic Syndromes
News
Elritercept demonstrates effective, durable responses across LR-MDS subgroups
Elritercept, an investigational modified activin receptor type IIA ligand trap, was well-tolerated and associated with rapid, durable transfusion and erythroid responses, including in
MDS News
SOHO 2026
Meetings / Conferences
Myelodysplastic Syndromes
Ofirnoflast improves transfusion burden, hemoglobin levels in LR-MDS
Ofirnoflast, a first-in-class allosteric NEK7 inhibitor, showed favorable safety and clinically significant efficacy in patients with low-risk myelodysplastic syndromes (LR-MDS) refractory to erythropoietin
MDS News
SOHO 2026
Meetings / Conferences
News
Study characterizes excess mortality and survival factors in RS–positive MDS
The study, led by Pina Gabriela Gálvez Zavala Registro, of Universidad Peruana Cayetano Heredia in Lima, Peru, compared patients in the Spanish Group